Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Novartis Signs Deal that Could Lead to Acquisition of Zurich Start-Up Cellerys
Details : Zurich-based Cellerys is working on new multiple sclerosis drug, CLS12311, which is currently in phase 2. Novartis is pairing up with the biotech on the asset but nabs the option to acquire Cellerys upon completion of a phase 2 trial in the coming years.
Product Name : CLS12311
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 06, 2021
Reset All
